{
    "clinical_study": {
        "@rank": "127931", 
        "arm_group": [
            {
                "arm_group_label": "Sequence B", 
                "arm_group_type": "Experimental", 
                "description": "Day 1:  Lesinurad 400 mg (manufactured at Site 2); Day 5: Lesinurad 400 mg (manufactured at Site 1)"
            }, 
            {
                "arm_group_label": "Sequence A", 
                "arm_group_type": "Experimental", 
                "description": "Day 1: Lesinurad 400 mg (manufactured at Site 1); Day 5: Lesinurad 400 mg (manufactured at Site 2)"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will assess the bioequivalence of lesinurad tablets manufactured at two different\n      sites."
        }, 
        "brief_title": "Lesinurad Tablet Bioequivalence", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "This study is intended to evaluate the clinical comparability of lesinurad tablets\n      manufactured at the 2 different sites by assessing relevant clinical Pharmacokinetics (PK)\n      parameters."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject has a body weight \u2265 50 kg (110 lbs.) and a body mass index \u2265 18 and \u2264 40\n             kg/m2.\n\n          -  Subject has a Screening serum urate level \u2264 7 mg/dL. \u02d7 Subject is free of any\n             clinically significant disease or medical condition, per the Investigator's judgment.\n\n        Exclusion Criteria:\n\n          -  Subject has any gastrointestinal disorder that affects motility and/or absorption.\n\n          -  Subject has a history or suspicion of kidney stones.\n\n          -  Subject has undergone major surgery within 3 months prior to Screening.\n\n          -  Subject has donated blood or experienced significant blood loss (> 450 mL) within 12\n             weeks prior to Day 1 or gave a plasma donation within 4 weeks prior to the Screening\n             visit.\n\n          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "54", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127775", 
            "org_study_id": "RDEA594-132"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Sequence B", 
                    "Sequence A"
                ], 
                "intervention_name": "Lesinurad 400 mg (manufactured at Site 1)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Sequence B", 
                    "Sequence A"
                ], 
                "intervention_name": "Lesinurad 400 mg (manufactured at Site 2)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 1, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78744"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Randomized, Open-Label, Crossover Study to Assess the Bioequivalence of Lesinurad Tablets From Two Manufacturing Sites in Healthy Adult Male Subjects", 
        "overall_contact": {
            "last_name": "C. Winnett", 
            "phone": "858.652.6649"
        }, 
        "overall_official": {
            "affiliation": "Ardea Biosciences, Inc.", 
            "last_name": "J. Hall", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PK endpoints in terms of maximum observed concentration (Cmax); time of occurrence of maximum observed concentration (tmax); area under the plasma concentration time curve from zero to 24 hours post dose (AUC last) and from zero to infinity (AUC \u221e); and apparent terminal half-life (t1/2). Point estimates and 90% confidence intervals for the ratio of geometric means for Cmax, AUC last and AUC\u221e between test and reference formulations.", 
            "measure": "PK profile of lesinurad from plasma", 
            "safety_issue": "No", 
            "time_frame": "Day 1 and Day 5"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127775"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Changes in Laboratory, Electrocardiogram and Vital Signs Parameters", 
            "measure": "Incidence of Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "5 weeks"
        }, 
        "source": "Ardea Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ardea Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}